Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 9:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Arrhythmia Prophylaxis Clear all
Recruiting Not applicable Interventional

Carotid Implants for PreveNtion of STrokE ReCurrEnce From Large Vessel Occlusion in Atrial Fibrillation Patients Treated With Oral Anticoagulation

NCT05723926
View directory record Official record
Conditions
Atrial Fibrillation, Oral Anticoagulation, Stroke, Implant
Interventions
Vine Filter
Device
Lead sponsor
Javelin Medical
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Rockford, Illinois • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 20, 2026, 9:20 PM EDT
Completed Phase 2Phase 3 Interventional

A Study of Stellate Ganglion Block for Prevention of Atrial Fibrillation

NCT05357690
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Stellate ganglion block, Bupivacaine, Placebo
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
60 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 20, 2026, 9:20 PM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 20, 2026, 9:20 PM EDT
Completed Phase 4 Interventional Results available

Prevention of Atrial Fibrillation Following Esophagectomy

NCT00420017
View directory record Official record
Conditions
Atrial Fibrillation, Esophagectomy
Interventions
Amiodarone, Control
Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
40 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Sep 20, 2026, 9:20 PM EDT
Recruiting Early Phase 1 Interventional

Prevention of Postoperative Atrial Fibrillation (POAF) Using Intra-Pericardial Amiodarone

NCT06063538
View directory record Official record
Conditions
Atrial Fibrillation, Post-Op Complication
Interventions
CardiaMend in Combination with Amiodarone
Combination Product
Lead sponsor
University of Chicago
Other
Eligibility
20 Years to 85 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 20, 2026, 9:20 PM EDT
Completed Phase 4 Interventional Results available

DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation

NCT02666742
View directory record Official record
Conditions
Ventricular Tachycardia, Premature Ventricular Contraction, Stroke
Interventions
DOAC, Aspirin
Drug
Lead sponsor
Kansas City Heart Rhythm Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Kansas City, Kansas • Overland Park, Kansas • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Sep 20, 2026, 9:20 PM EDT
Completed Not applicable Interventional Results available

Inappropriate Shock Reduction wIth PARAD+ Rhythm DiScrimination

NCT01410552
View directory record Official record
Conditions
Tachycardia
Interventions
PARADYM DR model 8550; PARADYM CRT model 8750; PARADYM RF DR model 9550; PARADYM RF CRT model 9750; PARADYM RF CRT SonR model 9770
Device
Lead sponsor
MicroPort CRM
Industry
Eligibility
18 Years and older
Enrollment
1,013 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
27
States / cities
Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Sep 20, 2026, 9:20 PM EDT
Completed Phase 3 Interventional Results available

A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation

NCT00174785
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
dronedarone (SR33589), placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
70 Years and older
Enrollment
4,628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 11, 2010 · Synced Sep 20, 2026, 9:20 PM EDT
Terminated Phase 3 Interventional Results available

Study of Amiodarone Given Before Lung Surgery to Prevent Atrial Fibrillation After Lung Resection

NCT00300495
View directory record Official record
Conditions
Atrial Fibrillation, Lung Cancer
Interventions
Amiodarone, Control arm, standard care
Drug · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Sep 20, 2026, 9:20 PM EDT
Completed Not applicable Interventional

Electronic Alerts for Stroke Prevention in Atrial Fibrillation

NCT02958943
View directory record Official record
Conditions
Atrial Fibrillation, Stroke
Interventions
On-screen electronic alert
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
798 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 7, 2022 · Synced Sep 20, 2026, 9:20 PM EDT
Completed Phase 2 Interventional

Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744c 100 or 300 mg for the Prevention of ventrICular ARrhythmia-triggered Icd interventiOnS

NCT00232297
View directory record Official record
Conditions
Arrhythmia, Tachycardia, Ventricular, Ventricular Fibrillation
Interventions
SSR149744C
Drug
Lead sponsor
Sanofi
Industry
Eligibility
21 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 7, 2012 · Synced Sep 20, 2026, 9:20 PM EDT
Completed Not applicable Interventional

Electronic Alerts for Stroke Prevention in Patients With Atrial Fibrillation or Atrial Flutter

NCT02339493
View directory record Official record
Conditions
Atrial Fibrillation, Stroke
Interventions
Computer Electronic Alert
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Sep 20, 2026, 9:20 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Azimilide in the Prophylactic Treatment of Patients With Atrial Fibrillation.

NCT00035464
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Azimilide Dihydrochloride, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
88
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2011 · Synced Sep 20, 2026, 9:20 PM EDT
Completed Phase 3 Interventional Results available

Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation

NCT00412984
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
warfarin, apixaban
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Not listed
Enrollment
20,976 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
284
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 206 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Sep 20, 2026, 9:20 PM EDT
Withdrawn Not applicable Interventional

Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF

NCT04684212
View directory record Official record
Conditions
Atrial Fibrillation, Left Atrial Appendage Thrombosis, CVA
Interventions
LAmbre PlusTM Left Atrial Appendage Closure System, Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)
Device · Drug
Lead sponsor
Brian O'Neill MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 20, 2026, 9:20 PM EDT
Not listed Phase 3 Interventional

Cardiac Sympathetic Denervation for Prevention of Ventricular Tachyarrhythmias

NCT01013714
View directory record Official record
Conditions
Sudden Cardiac Death, Ventricular Tachycardia, Ventricular Fibrillation, Cardiomyopathy
Interventions
Cardiac Sympathetic Denervation (CSD), Routine Care
Procedure · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Los Angeles, California • Portland, Oregon • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Sep 20, 2026, 9:20 PM EDT
Terminated Phase 3 Interventional Results available

Catheter Ablation Versus Amiodarone for Shock Prophylaxis in Defibrillator Patients With Ventricular Tachycardia

NCT01097330
View directory record Official record
Conditions
Defibrillators, Implantable, Tachycardia, Ventricular
Interventions
Ablation, Amiodarone
Procedure · Drug
Lead sponsor
Population Health Research Institute
Other
Eligibility
19 Years to 84 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Chicago, Illinois • Rochester, Minnesota • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Sep 20, 2026, 9:20 PM EDT
Completed Phase 2 Interventional

Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence

NCT00267930
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Vernakalant (oral), Placebo comparator
Drug
Lead sponsor
Advanz Pharma
Industry
Eligibility
18 Years to 85 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
4
States / cities
Huntsville, Alabama • Walnut Creek, California • Hershey, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2008 · Synced Sep 20, 2026, 9:20 PM EDT
Terminated Phase 3 Interventional

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)

NCT00243178
View directory record Official record
Conditions
Atrial Fibrillation, Vascular Risk
Interventions
clopidogrel (SR25990C)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
6,706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 18, 2009 · Synced Sep 20, 2026, 9:20 PM EDT
Completed Phase 3 Interventional Results available

Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation

NCT00970489
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Omega -3 fatty acids, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
1,516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2017 · Synced Sep 20, 2026, 9:20 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Magnesium Supplementation for the Prevention of Supraventricular Arrhythmias

NCT02837328
View directory record Official record
Conditions
Premature Atrial Contraction
Interventions
Oral Magnesium Supplement, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
55 Years and older
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Sep 20, 2026, 9:20 PM EDT
Completed No phase listed Observational

Real-world Comparative Effectiveness of Apixaban Versus Vitamin K Antagonist

NCT02687854
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Apixaban, Vitamin K antagonist
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
18,591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Sep 20, 2026, 9:20 PM EDT
Not listed Phase 4 Interventional

Efficacy of Different Anti-Thrombotic Strategies on Device-Related Thrombosis Prevention After Percutaneous Left Atrial Appendage Occlusion

NCT04502017
View directory record Official record
Conditions
Device-Related Thrombosis, Atrial Fibrillation, Left Atrial Appendage Occlusion
Interventions
ASA plus Clopidogrel, Genetic-Tailored AntiThrombotic Strategy, Half-Dose of novel OAC
Drug
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Sep 20, 2026, 9:20 PM EDT
Completed Phase 2 Interventional Results available

Odiparcil For The Prevention Of Venous Thromboembolism

NCT00244725
View directory record Official record
Conditions
Deep Vein Thrombosis, Fibrillation, Atrial, Venous Thromboembolism, Pulmonary Embolism
Interventions
Odiparcil, Warfarin, Coumadin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
35 Years and older
Enrollment
961 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
46
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Sep 20, 2026, 9:20 PM EDT